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The human herpesvirus 8 (HHV8/KSHV), along with certain other herpesviruses, encodes a gene with cyclin homology.
Although the functional significance of the encoded cyclin is not clear at present, various lines of evidence propose a role
for this cyclin in latently infected cells and possibly in the induction of tumors that arise in HHV8-infected individuals. We
provide evidence here that the cyclin protein is expressed in HHV8 positive primary effusion lymphoma (PEL)-derived cell
lines and that its level of expression varies greatly between different lines. Our analysis indicates that the level of cyclin
protein expression in different PEL cell lines may correlate with the level of transcript expression during latency but not in
cells induced to undergo lytic replication. In highly expressing BC-3 cells the cyclin is complexed with cdk6, cdk4, cdk2, and
cdk5 under both latent and lytic conditions, although subtle changes in the level of cdk association are seen after induction
of the lytic cycle. Altogether our findings support the notion that the cyclin is a latency-associated gene product expressed
in PEL tumor cells. They furthermore indicate that after lytic cycle induction, the level of cyclin transcript expression may not
be a reliable indicator for the level of cyclin protein expression. © 2000 Academic Press
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1INTRODUCTION
Kaposi’s sarcoma herpesvirus or human herpesvirus 8
(KSHV/HHV8) is a member of the Rhadinovirus group of
gamma herpesviruses. Infection by this virus is strongly
implicated in the cause of hyperplastic and neoplastic
diseases in humans. These are Kaposi’s sarcoma (KS),
an initially polyclonal hyperplasia of most likely endothe-
lial origin; primary effusion lymphoma (PEL), a rare lym-
phoma arising concurrent with HIV infection; and a plas-
mablastic variant of Castleman’s disease (MCD), an
atypical polyclonal lymphoproliferative disorder with of-
ten fatal outcome.
Fragments of HHV8 DNA were initially discovered in
KS tissue (Chang et al., 1994). Since then, the presence
of HHV8 sequences has been consistently found in KS
tissues (Boshoff et al., 1995; de Lellis et al., 1995; Moore
and Chang, 1995; Schalling et al., 1995), PEL cells (Ce-
sarman et al., 1995; Nador et al., 1995), and frequently in
lymphocytes from Castleman’s disease (Karcher and Al-
kan, 1995; Soulier et al., 1995). Epidemiological evidence
trongly suggests that HHV8 is instrumental in the de-
elopment of all these types of disease, although other
ofactors may also be involved, (reviewed in Chatlynne
nd Ablashi, 1999; Schulz, 1999).
Like several other rhadinoviruses, HHV8 carries a
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257umber of genes of apparently cellular descent (Arvani-
akis et al., 1996; Cesarman et al., 1996; Cheng et al.,
997; Gao et al., 1996; Murphy, 1997; Sarid et al., 1997;
reviewed in Moore and Chang, 1995; Neipel et al., 1997;
Russo et al., 1996). One of these is a protein with simi-
larity to cellular D-type cyclins (Cesarman et al., 1996;
Chang et al., 1996; Godden-Kent et al., 1997; Li et al.,
1997). Cyclins are regulatory subunits that complex and
activate cyclin dependent kinases (cdks) (reviewed in
Pines, 1996). Kinase activation by D-type cyclins is pre-
sumed to be a key requirement for entry of cells into S
phase, and the deregulation of these kinases has been
implicated repeatedly in human neoplasia (reviewed in
Hall and Peters, 1996; Sherr, 1996).
Various lines of evidence suggest that the HHV8-en-
coded D-type cyclin (vcyc) can deter cellular growth
control in many ways and, through this, may contribute to
HHV8 inflicted malignancies. Experimental expression of
vcyc in tissue culture systems demonstrated its ability to
activate cellular cdks, resulting in a kinase resistant to
cyclin-dependent kinase inhibitors (Swanton et al., 1997)
and able to mediate phosphorylation and inactivation of
the retinoblastoma protein (Chang et al., 1996), destabi-
lization of the cyclin-dependent kinase inhibitor p27 KIP
(Ellis et al., 1999; Mann et al., 1999), and entry of cells into
S phase in the absence of growth factors (Swanton et al.,
1997). These features suggest that expression of the
vcyc protein may obstruct cell proliferation control and
prevent cell cycle exit in response to extracellular cues.
Through this, it may preserve the proliferation capacity of
0042-6822/00 $35.00
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258 PLATT ET AL.latently infected cells and at the same time augment
HHV8-associated hyperplasia.
RNA encoding vcyc is found in latently infected PEL
cells and in primary KS (Cesarman et al., 1996; Cobo et
al., 1999; Flore and Gao, 1997; Reed et al., 1998; Sturzl et
al., 1999). However, vcyc protein expression has not
been demonstrated to date. In latently infected PEL cell
lines, vcyc appears to be encoded by at least three
different transcripts a major one of 2 kb (LT-2) and two
minor ones of 6 kb (LT-1) and 1 kb (Dittmer et al., 1998;
Sarid et al., 1997; Talbot et al., 1999). Only LT-1 and LT-2
have been characterized in detail thus far. They derive
from the same transcriptional start site, are generated by
alternative splicing, and encompass reading frames for
more than one gene. LT2 encodes ORF 72/vcyc as well
as the adjacent reading frame for ORF K13/vFLIP. In
addition to these, LT-1 encompasses sequences for the
major latent antigen ORF73 (LANA). Although the pres-
ence of LANA protein has been amply demonstrated in
KS tumours and PEL cells (Callahan et al., 1999; Couty et
al., 1999; Gao et al., 1996; Katano et al., 1999; Rainbow et
al., 1997), it is not clear whether and to what extent the
protein products vcyc or vFLIP are produced.
We generated anti-vcyc antibodies and used these to
study vcyc expression in a number of different PEL cell
lines. Our results indicate that the vcyc protein is present
in these cells and is expressed during viral latency but
that the level of vcyc expression varies greatly between
different cell lines.
RESULTS
Cyclin antibody characterization and detection of vcyc
in PEL cell lines.
We used recombinant full-length vcyc expressed as a
glutathione-S-transferase (GST) fusion protein in Esche-
richia coli as an antigen to produce a rabbit serum as
well as a monoclonal antibody with reactivity to vcyc.
Both of these reagents specifically reacted in Western
blots with recombinant vcyc produced by baculovirus but
neither recognized cellular D-type cyclins produced in an
identical manner (Fig. 1A).
To address whether the cyclin protein is expressed in
HHV8-infected PEL cells, we probed Western blots con-
taining lysate from two different HHV8-positive PEL-de-
rived cell lines, BC-3 (Arvanitakis et al., 1997) and BCP-1
(Boshoff et al., 1995); several HHV8 negative leukemia
lines; and an EBV immortalized B cell line, LCL3 (Fig. 1B).
Both the rabbit serum and the monoclonal antibody rec-
ognized a protein in BC-3 of roughly 28 kDa, which was
slightly smaller than the 9E10 tagged recombinant vcyc
protein expressed in mammalian (Fig. 1B, top, lane 8) or
insect cells (Fig. 1B, bottom, lane 8). We note that the
presence of the 9E10 tag attached to the amino-terminus
of the recombinant cyclin proteins is expected to in-
crease their size by approximately 2 kDa.The 28-kDa protein detected in BC-3 lysate was not
apparent in any of the other cell lines, including BCP-1,
although this cell line has been reported to contain HHV8
DNA (Boshoff et al., 1995) and to express vcyc transcripts
(Talbot et al., 1999). Control blots using anti-tubulin anti-
body show that the absence of the prospective vcyc
signal in BCP-1 and the HHV8-negative leukemia lines
was not due to underloading of the lanes. A very similar
signal was obtained throughout all lanes that contain cell
lysates when the respective blots were counterprobed
using anti-tubulin antibody (Fig. 1B).
To confirm that the 28- kDa signal detected by the two
different anti-vcyc reagents in BC-3 lysate is due to
recognition of the same protein, we performed reciprocal
immunoprecipitations followed by Western blots (Figs.
2A and 2B). We found that both the rabbit serum and the
monoclonal antibody precipitate proteins of the correct
FIG. 1. Detection of anti-vcyc reactive protein in baculovirus-infected
insect cells and HHV8 containing lymphoma lines. (A) Lysate from
insect cells infected with recombinant baculoviruses encoding the
cyclin–cdk complexes as indicated were subjected to Western blot
analysis. Blots were probed with anti-vcyc rabbit serum [anti-vcyc (R),
top panel] or the anti-vcyc monoclonal antibody (anti-vcyc 94B, middle
panel). Blots were counterprobed with 9E10 antibody, recognising an
amino-terminal tag present on all of the recombinant cyclins. vcyc
denotes viral cyclin; cycD1, cycD2, and cycD3 denote human cyclins D1,
D2, and D3; cdk4 and cdk6 denote expression of cyclin-dependent
kinase subunits 6 and 4. Numbers on the left indicate the position of
size markers. (B) Western blots containing lymphoma cell lysates were
analysed using the cyclin antibodies. Lysate from transfected U2OS
cells (lanes 7 and 8, top) or vcyc-expressing insect cells (lanes 7 and
8 bottom) were loaded as a positive control. Blots were counterprobed
using anti-tubulin antibodies to demonstrate equal loading. Cell used
were BCP-1 and BC-3 (HHV8 positive, PEL derived), LCL3 (EBV immor-
talised B cells), and Reh and Nalm-6 (pre-B lymphoblastoid leukemia
derived). Use of antibodies was as in A.size that are recognized by the reciprocal immunore-
agent. This occurs under native conditions as well as
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259HHV8 CYCLIN PROTEIN EXPRESSIONwith lysate that had been denatured by boiling in SDS,
indicating that the precipitated protein is recognized di-
rectly by the respective immunoreagent and is not pre-
cipitated by virtue of its association with another lysate
component.
To confirm that the 28-kDa protein observed in BC-3
cell lysate is immunologically related to the vcyc protein,
we performed Western blots in the presence of GST–
vcyc antigen or uninfused GST as competitor (Fig. 2C).
Both the rabbit serum and the monoclonal antibody rec-
ognized the 28-kDa protein in BC-3 or the slightly larger
vcyc protein expressed from recombinant baculovirus
when uninfused GST was used as a competitor. In con-
trast, recognition of these antigens is either abolished or
substantially reduced in the presence of GST–vcyc. To-
gether, these experiments indicate that both reagents
recognize the same 28-kDa protein in the BC-3 cell
lysate and that this protein is antigenically related to the
recombinant HHV8 cyclin, used as an immunogen.
The vcyc transcript levels in BC-3 and BCP-1
Our previous results indicated that the vcyc is avidly
expressed in BC-3 cells but not, or to a vastly lower
FIG. 2. Validation of the anti-vcyc immunoreactivity. (A and B) BC-3
lysate was precipitated using either the anti-vcyc monoclonal antibody
94B (94B) or the anti-vcyc rabbit serum [vcyc(R)]. The lysate was either
used native (nat) or denatured by boiling in SDS (denat); buffer denotes
omission of lysate and serves to control for background arising from
the antibody–beads complexes. Precipitates were subjected to West-
ern blot analysis and probed with the reciprocal immunoreagent. Lanes
1 and 2 contain input lysate of BC-3 and BCP-1. (C) Antigen competition.
Western blots were produced using lysates as indicated and probed
using the anti-vcyc reagents [94B; vcyc (R)] in the presence of either E.
coli produced GST–cyclin fusion protein (GST-vcyc) or uninfused GST
(GST) as a competitor; bv denotes use of baculovirus-directed insect
cell lysate.extent, in BCP-1 cells. In contrast, recent reports
clearly demonstrate that vcyc encoding transcripts arepresent in BCP-1 cells (Talbot et al., 1999). To confirm
he presence of vcyc encoding transcripts in our
CP-1 cells and to investigate whether the difference
n vcyc protein expression could be explained by dif-
erent expression levels of vcyc encoding mRNA, we
solated polyadenylated RNA from both BC-3 and
CP-1 cells. Western blots of protein extracts prepared
n parallel showed that the vcyc was clearly detectable
n BC-3 but not in BCP-1 cells (Fig. 3A). To accurately
uantify the amount of vcyc encoding transcripts
resent in both cell lines, we performed RNA slot blots
Fig. 3B). Using the ORF72/vcyc reading frame as a
robe, a large difference in signal intensity became
FIG. 3. HHV8 vcyc transcript and protein levels in BC-3 and BCP-1
cells. RNA and protein lysates were produced from two independent
batches of BC-3 and BCP-1 cells (exp. 1 and exp. 2). (A) Western blot
analysis of protein lysates. Antibodies used are as indicated. (B) RNA
slot blot analysis. Equal amounts of poly(A) RNA were denatured in 40%
formamide–formaldehyde and blotted onto nylon membrane using a
manifold multiblot apparatus. Blots were probed with a vcyc probe or a
fragment of the cellular gene GAPDH. (B9) RT–PCR analysis. RNA from
experiment 2 was reverse transcribed and amplified using cyclin prim-
ers. PCR products were separated by agarose gel electrophoresis,
blotted onto membrane, and probed using the vcyc probe. RT denotes
the presence or absence of reverse transcriptase in the reactions,
respectively. (C) PhosphorImager-based quantification of the slot blot
analysis shown in B. The vcyc values shown are normalised to GAPDH
(vcyc/GAPDH).
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260 PLATT ET AL.apparent between the two cell lines. In contrast, a
probe detecting cell-encoded GAPDH transcripts
yielded a very similar signal in both instances. PCR on
reverse transcribed RNA (Fig. 3B9) confirmed that the
difference in vcyc signal was not due to contamination
of our RNA preparation with viral DNA. The PCR signal
obtained was strictly dependent on the use of reverse
transcriptase, indicating the absence of viral DNA in
the preparation. Together, these results suggest that
although vcyc transcripts are clearly present in BCP-1
cells, their amount is significantly lower than in BC-3.
Quantification by phosphorimaging shows that BCP-1
cells express in the order of sevenfold fewer vcyc
encoding transcripts (Fig. 3C). This relatively low vcyc
transcript abundance could explain the absence of
detectable vcyc protein expression in BCP-1 cells.
The vcyc protein expression after lytic cycle induction
Recent work, based on analysis of PEL-derived BC-1
cells, indicated that induction of lytic virus replication did
not affect the level of vcyc transcript expression (Sarid et
al., 1997). In contast, other work, using BCP-1 or BCBL-1
cells, reported increased expression of the bicistronic
vcyc encoding transcript, LT-2, and to a lesser extent the
tricistronic transcript, LT1 (Dittmer et al., 1998; Talbot et
l., 1999). This could suggest that there exists a cell
ine-specific difference in the production of vcyc encod-
ng transcripts, and possibly protein. More specifically,
ome PEL cell lines may express high levels of vcyc
ranscripts (and consequently, vcyc protein) during la-
ency, whereas this expression in others may require
nduction of the lytic cycle. To address whether such
ifferences may be responsible for the differences in
cyc transcript and protein levels, we extended our anal-
sis to include BCP-1 and BC-3 cells exposed to TPA for
8 h. We found that TPA treatment of BCP-1 cells, in
ccordance with recently published observations (Talbot
t al., 1999), leads to a rise in vcyc encoding transcript
evels (Figs. 4B and 4C). Quantification of the RNA slot
lot signal indicates an increase of these transcripts by
ivefold in comparison with mock-treated controls. How-
ver, despite this, expression of the vcyc protein was not
etectable in TPA-treated BCP-1 cells.
Only a mild increase in vcyc transcript and no changes
n vcyc protein levels were apparent on TPA treatment of
C-3 cells (Figs. 4A and 4B). We note that vbcl2 tran-
cripts were induced to the same level in BCP-1 and
C-3 cells, indicating that lytic induction has occurred in
oth cell types. Furthermore, RT–PCR analysis in the
bsence or presence of reverse transcriptase confirmed
hat as in the previous analysis, the RNA preparations
ere free of contaminating viral DNA.
Based on the above analysis (and in accordance withecently published observations), it would appear that
cyc encoding transcripts may indeed be induced in the
b
vourse of lytic cycle induction in certain cell lines. How-
ver, even though the levels of vcyc transcripts on induc-
ion in BCP-1 approached levels comparable to those in
C-3, vcyc protein expression remained undetectable.
his in turn indicates that transcripts accumulating dur-
ng the lytic replication cycle in BCP-1 may not lead to a
roportional increase in vcyc protein synthesis. It also
ndicates that vcyc transcript levels may not necessarily
FIG. 4. HHV8 vcyc transcript and protein levels in cells induced to
support lytic HHV8 replication. BCP-1 and BC-3 cells were either
treated with TPA for 48 h or with DMSO for an uninduced control.
Lysates for protein analysis and poly(A) RNA were prepared and ana-
lysed as for Fig. 3. (A) Western blot analysis of cell lysates. Parallel
blots were probed with anti-cyclin rabbit serum [anti-vcyc (R)], the 94B
anti-vcyc monoclonal antibody (94B), or anti-tubulin antibody. (B) RNA
slot blot analysis. Blots were probed for vcyc, vbcl2, or GAPDH. (B9)
RT–PCR analysis using vcyc primers. RT denotes use of reverse tran-
scriptase. (C) PhosphorImager-based quantification of the slot blot
analysis shown in B. Values shown are normalised with respect to the
GAPDH signal.e a valid indicator as to the level and/or presence of
cyc protein expression.
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261HHV8 CYCLIN PROTEIN EXPRESSIONBiochemical features of the BC-3 expressed anti-vcyc
reactive protein
To test whether the BC-3 protein has biochemical
properties in accordance with those established previ-
ously for recombinant vcyc, we tested whether this pro-
tein copurified with cdk6, a kinase unit that is bound and
activated by recombinant vcyc (Godden-Kent et al., 1997;
i et al., 1997; Swanton et al., 1997). We found that the
28-kDa protein is precipitated with an anti-cdk6 antibody
from native BC-3 cell lysate but not from lysate that had
been heat-denatured before cdk6 precipitation (Fig. 5A).
We note that equal amounts of cdk6 are precipitated
under native and denaturing conditions. These experi-
ments indicate that the 28-kDa protein is in a complex
with cellular cdk6 and thus shares functional features
with recombinant vcyc.
To determine whether the majority or only a portion
of the putative vcyc is complexed to cdk6, we depleted
cdk6 from the BC-3 cell lysate using anti-cdk6 immu-
nobeads (Fig. 5B). Although this treatment resulted in
removal of the majority of the cdk, the amount of vcyc
remaining in the supernatant was barely altered, rais-
ing the possibility that the vast majority of vcyc protein
in these cells is either free or in complexes with
proteins other than cdk6 (Fig. 5B). To assess the de-
gree of free and complexed vcyc, BC-3 cell lysate was
subjected to a gel filtration analysis followed by West-
ern blotting (Fig. 5C). This demonstrated that some of
the protein indeed migrated with an apparent native
size of 30 kDa (fraction 19) and thus is likely to be
monomeric. A greater portion, however, migrated at a
molecular size of greater than 100 kDa (fractions 16
and 17), which closely resembles the native size of
cellular D-type–cdk complexes (Parry et al., 1999), in-
dicating that this portion of vcyc may be complexed to
either cdks or other similar sized proteins.
Previous experiments using overexpression in COS
monkey kidney cells indicated that vcyc can associate
with other cdks apart from cdk6 (Godden-Kent et al.,
1997; Li et al., 1997). To address whether this is also the
case for the authentic vcyc, we conducted immunopre-
cipitation experiments using antibodies against a range
of other cdks. We found clear evidence for the existence
of vcyc in complexes with cdk2, cdk4, and cdk5 (Fig. 5D).
No association with cdk1, cdk7, cdk8, or cdk9 could be
demonstrated, although these cdk subunits were effi-
ciently precipitated by their respective antibodies (data
not shown). These experiments establish that the puta-
tive vcyc protein in BC-3 cell lysate can associate with a
spectrum of cdks apart from cdk6. This spectrum is in
accordance with predictions derived from previous ex-
periments with recombinant vcyc protein (Godden-Kent
et al., 1997; Li et al., 1997). We note that these experi-ents do not allow conclusions as to the relative degree
f association with the respective cdks or the contribu-tion of these complexes to the overall activity. Neither of
our anti-vcyc antibodies was able to precipitate a vcyc–
cdk complex or an active kinase from BC-3 cell lysate or
recombinant source, which precluded us from establish-
ing these facts.
To address whether the cdk association changes as a
result of lytic virus replication, we extended our analysis
to BC-3 cells exposed to TPA for 48 h to induce lytic virus
replication. We found that the same spectrum of cdks
associated with the vcyc protein under both latent and
lytic conditions. We note, however, that the degree of
cdk4 association (and to a lesser extent, that with cdk5)
increased in lytic cells. Densitometry of underexposed
autoradiographs (not shown) indicates a threefold in-
crease in the amount of vcyc present in anti-cdk4 pre-
cipitates and twice the amount in cdk5 precipitates in
lytic (with TPA) versus mock-induced (without TPA) ly-
sate. Increased association with theses cdks was con-
sistently seen with independent lysate preparations.
Similar amounts of the respective kinases were present
in the precipitates (Fig. 5E, bottom), and neither the
overall amount of vcyc nor the amount of the respective
cdks present in lysate changed significantly during lytic
induction (not shown, also see Fig. 4). These results
could indicate that critical changes in vcyc function occur
during the lytic replication cycle.
The vcyc protein expression in other PEL-derived
lines
To address whether the high level of vcyc protein
expression is exceptional for BC-3 cells or is more widely
seen in PEL lines, we analyzed a further four primary
effusion lymphoma lines using Western blotting. Further-
more, to increase the chances of detecting low-level vcyc
expression, we prepared all cell lysates fivefold more
concentrated with respect to cell numbers. Analysis of
these concentrated samples showed that only BC-3 cells
expressed high amounts of the vcyc protein, yet under
such conditions of increased sample loading, a faint
signal at the correct molecular weight was apparent in
all PEL-derived cell lines, including BCP-1, but absent in
HHV8-negative LCL3 cells. Thus the HHV8 vcyc protein
is expressed in BCP-1 and other PEL-derived cell lines,
although at a significantly lower level.
To assess the relative degree of vcyc expression in the
various PEL-derived cell lines, we repeated the Western
analysis, including a serial dilution of the BC-3 cell lysate
(Fig. 6C). As before, a weak but significant signal was
obtained from all PEL-derived cell lines. This signal was
clearly weaker in intensity than that obtained with BC-3
lysate diluted ninefold. This indicates that all PEL cell
lines analysed here express vcyc protein but that the
amount of vcyc that accumulates in the majority of these
cells is more than ninefold lower than that in BC-3 cells.
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262 PLATT ET AL.FIG. 5. Biochemical characterisation of the BC-3-expressed anti-vcyc reactive protein. (A) Association with cdk6. Native or denatured BC-3 lysates
ere immunoprecipitated using anti-cyclin-dependent kinase 6 (cdk6) antiserum. Immunoprecipitates were subjected to Western blot analysis and
robed using anti-vcyc monoclonal antibody 94B (top panel). Subsequently, blots were counterprobed using anti-cdk6 (bottom panel). Lane 1 contains
C-3 input lysate; buffer denotes precipitation in the absence of cell lysate. (B) cdk6 depletion analysis. Lysates were depleted for cdk6 by two
onsecutive treatments with anti-cdk6 bound to Protein A–Sepharose. Western blots were conducted and analysed as in A. BC-3 denotes untreated
ysates; Beads 1 and Beads 2 denote material recovered from the anti-cdk6–Sepharose after incubation with lysate; T0 denotes lysate before the
ddition of antibody; and T2 denotes lysate after two consecutive treatments with anti-cdk6. Note that lanes featuring beads were loaded using half
he amount of material recovered, whereas only 1/10 of the total was loaded in lanes containing lysate. (C) Size fractionation of BC-3 cell lysates. BC-3
ysates were fractionated using gel filtration on Superdex 75. Fractions were subjected to Western blot analysis using 94B or a mixture of anti-cyclin
1, D2, and D3 antibodies. The size and position of gel filtration size markers are indicated on the top. (D) Spectrum of associated cdks. Native or
enatured BC-3 lysates were immunoprecipitated using anti-cdk2, cdk4, and cdk5 antisera. All subsequent analysis was as described in A. (E) cdk
ssociation after induction of lytic virus replication. Cells were either treated with TPA for 48 h (1TPA) or with DMSO (2TPA) for an uninduced control.
Analysis was essentially performed as outlined in A and D.
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We demonstrate in this report that the HHV8-encoded
yclin protein is expressed in various cell lines derived
rom PEL. Various previous reports showed the presence
f vcyc encoding transcripts in PEL lines and, further-
ore, in KS biopsies (Cesarman et al., 1996; Cobo et al.,
1999; Dittmer et al., 1998; Flore and Gao, 1997; Rainbow
et al., 1997; Reed et al., 1998; Sarid et al., 1997; Sturzl et
l., 1999; Talbot et al., 1999). More detailed analysis
evealed that the bulk of these transcripts is polycis-
ronic, encompassing, in addition to the cyclin reading
rame, sequences derived for the neighbouring reading
rames and leaving open whether any of these tran-
cripts result in the translation and expression of the
cyc protein in these cells.
This would appear to be an issue of crucial impor-
ance. Experimental expression of recombinant vcyc pro-
ein in tissue culture cells repeatedly demonstrated that
his cyclin, presumably via activation of the cellular cdk6
ubunit and others, is able to override cell cycle regula-
ory mechanisms and in substantial ways can affect the
rowth properties of cells. These observations in turn led
o the proposal that vcyc protein expression in cells
atently infected with HHV8 could deter, via analogous
echanisms, cell proliferation control, thus positively
nfluencing tumor formation consequential to HHV8 in-
ection.
Missing links in support of such a notion are, first,
hether not only transcripts but also vcyc protein is
FIG. 6. HHV8 vcyc expression in different PEL-derived cell lines. Cell
lysates were prepared from cell lines as indicated. Lysates were
prepared fivefold more concentrated than those for the previous ex-
periments. LCL3 denotes use of the HHV8-negative EBV immortalised
B cell line. All other cell lines are PEL derived and HHV8 positive. (A)
Western blots were probed using 94B anti-vcyc or anti-tubulin mono-
clonal antibodies. (B) Reanalysis of the samples shown in A. BC-3
lysate was loaded concentrated (lane 8) and as threefold serially
diluted (lanes 6 and 7). Blots were probed with 94B anti-vcyc antibody.resent in tumor cells and, second, whether this protein
licits biochemical features as predicted by the recom-
c
cinant work. The work presented in this report provides
nswers to both of these questions. We provide evidence
hat vcyc protein is expressed in PEL-derived cell lines.
oreover, our experiments show that congruent with
redictions from the recombinant work, this vcyc protein
orms complexes with cdk6 and, furthermore, a spectrum
f other cdks, including cdk5, cdk4, and cdk2 in these
ells. These complexes are clearly seen in both latently
nfected BC-3 cells and after lytic cycle induction. Our
nalysis indicates that the abundance of certain com-
lexes increases after treatment that triggers entry into
he lytic virus cycle. We note that routine examination of
PA-treated BC-3 cells by immunofluorescence using
ntibodies against the late gene product K8.1 indicate
hat in accord with published results (Zhu et al., 1999),
nly 12–15% of all these cells eventually become positive
nd thus may have supported virus replication success-
ully. Given the rather substantial (threefold) increase in
dk4 association with vcyc, this raises issues as to
hether the changes concerned can possibly be con-
ined and explained by this small number of cells under-
oing viral replication. Our current ignorance as to vcyc–
dk complex stoichiometry does not allow us to make
irm predictions in this regard.
Our analysis indicates that vcyc is expressed in five
ut of five PEL cell lines, although the level of vcyc
rotein expressed varies substantially between the dif-
erent lines. Specifically, one of these cell lines, BC-3,
xpresses at least nine times more vcyc than any of the
ther lines examined. More subtle variations are seen
etween the remaining lines. Such different levels of
cyc protein expression may be explained, at least in
art, by a different level of transcript expression as indi-
ated by our analysis of RNA from high expressing BC-3
nd low expressing BCP-1. However, we note that induc-
ion of virus replication in BCP-1 raised the vcyc tran-
cript quantity to levels comparable to BC-3, yet did not
esult in a visible increase in vcyc protein expression.
his observation suggests that additional, posttranscrip-
ional mechanisms may exist in HHV8-infected cells that
ontrol the level of vcyc protein accumulation. Such con-
rols could be exercised by expression of different tran-
cript species with a different potential to translate the
cyc reading frame or rely on more sophisticated mea-
ures such as inhibition of ribosome entry or different
rotein stability.
Of more importance would seem to be whether the
egree of vcyc protein expression has functional impli-
ations. As far as the cell encoded cyclins are con-
erned, current evidence suggests that not only their
resence but also their finite level is of great significance
Roberts, 1999). A mechanism that could explain such
ose effects has been established in detail for the cel-
ular D-type cyclins. A certain level of this group of
yclins would seem to be required to generate cyclin–
dk complexes that act as a reservoir for p27KIP inhibi-
264 PLATT ET AL.tors, which accumulate in resting and quiescent cells.
Cyclin accumulation beyond a certain threshold,
achieved via gene activation and through pathways in-
volving growth factor receptor signaling and expression
of the c-myc oncoprotein, is essential for the activation of
cyclin E kinase and successful progression through the
proliferation cycle (Bouchard et al., 1999; Cheng et al.,
1998; Perez-Roger et al., 1999).
However, it has been clearly demonstrated that
p27KIP does not bind to cdk complexes formed by vcyc
(reviewed in Swanton et al., 1997). In turn, the resulting
kinase activity may eliminate p27KIP via phosphorylation
and destabilization, a catalytic operation that may elimi-
nate the inhibitor even under conditions where the
amount of cyclin–cdk complex is substoichiometric to
that of p27KIP. It would, however, seem valid to conclude
that a lower level of cyclin protein will translate into a
lower level of kinase activation and thus a reduced rate
of catalysis. Whether this is truly so and whether this
could affect the growth characteristic of PEL cells or
correlate with progression or prognosis of disease re-
mains to be established.
MATERIALS AND METHODS
Cell culture
PEL-derived cell lines BC-3 (Arvanitakis et al., 1997),
HBL-6/BC-1 (Cesarman et al., 1995), ISI-1 (Oksenhendler
et al., 1998), BCBL-1 (Kedes and Ganem, 1997), and
BCP-1 (Boshoff et al., 1995) were obtained from E. Ce-
sarman (Cornell University, NY), C. Boshoff (UCL, Lon-
don, UK), F. Agbalika (Hopital Saint-Louis, Paris, France),
and T. Schulz (University of Liverpool Medical School,
UK). The EBV immortalized B cell line, LCL3 (Allday et al.,
1995), was a gift from P. Farrell (Ludwig Institute, St.
Maries Branch, London, UK). The pre-B acute lympho-
blastoid leukemia cell lines Reh and Nalm-6 were ob-
tained from M. Greaves (LRF, London, UK).
All leukemia-derived cell lines were maintained in
RPMI 1640 medium supplemented with 15% fetal calf
serum. Lysates were prepared from actively growing
cultures, freshly subcultured 36 h before harvest. To
trigger lytic virus replication, freshly subcultured BC-3
and BCP-1 cells were treated with 20 ng/ml TPA. DMSO
was used in place of the TPA for noninduced controls.
Induction of the lytic cycle was confirmed by probing
RNA, extracted in parallel from a portion of cells with a
probe for the early lytic gene encoding ORF16 (vbcl2).
U2–0S osteosarcoma cells were used for the transient
expression of recombinant vcyc and maintained in Dul-
becco’s modified Eagle’s medium. Transfection of vcyc
expression constructs was as described (Ellis et al.,
1999). Insect cell culture and the production of recombi-
nant protein by baculovirus have been described (God-
den-Kent et al., 1997).Antibodies and immunoreagents
Tag-specific anti-c-myc (9E10) antibody was purified
from tissue culture supernatant using chromatography
on DEAE-Sepharose. Antibodies against cdk1 (cdc2),
cdk2, cdk5, cdk6, cdk7, cdk8, and cdk9 were purchased
from Santa Cruz (Santa Cruz, CA). All were raised against
C-terminal peptide epitopes of the respective kinases
and chosen because of their known ability to precipitate
endogenous cyclin–cdk complexes in an active form.
Anti-tubulin monoclonal antibody was purchased from
Sigma Chemical (Poole, Dorset, UK). Anti-rabbit and anti-
mouse horseradish peroxidase-coupled secondary anti-
bodies were obtained from Pierce Chemical (Rockford,
IL).
Production of anti-cyclin antibodies
The coding region of vcyc was excised from pcDNA3
9E10 vcyc (Ellis et al., 1999) using EcoRI and subcloned
into the pGex6P1 (Pharmacia Biotech, Uppsala, Sweden)
to allow production of the cyclin fused to GST in E. coli.
The vector was transformed into pLys bacteria, and the
fusion protein was produced as described (Zarkowska
and Mittnacht, 1997) with the following modifications.
After binding of the fusion protein to glutathione–Sepha-
rose beads, the beads were washed in 10 volumes of
lysis buffer, and the bound fusion was eluted in 100 mM
Tris–Cl, pH 8.0, 25 mM glutathione and subjected to
chromatography on Mono Q to remove any uninfused
GST protein. Rats and rabbits were injected with 50 mg
of purified fusion protein. Subsequent boosts were per-
formed at 4-week intervals. The production of rat mono-
clonal antibodies followed standard procedures (Harlow
and Lane, 1988). Rabbit serum was used unpurified. The
anti-vcyc monoclonal antibody 94B was purified from
hybridoma cell tissue culture supernatant by DEAE-
Sepharose chromatography.
Preparation of cell lysate, gel filtration, and
immunoprocedures
Suspension cells were harvested by centrifugation,
washed in PBS, and lysed at 1–5 3 106 cells/ml in HB (25
mM HEPES, pH 7.0, 20 mM EDTA, 150 mM NaCl, includ-
ing the protease inhibitors leupeptin, phenylmethylsulfo-
nyl fluoride, and aprotinin). Lysates were stored at
270°C. Before use, cell debris was removed by centrif-
ugation at 10,000 g. For Western blot analysis, samples
were fractionated on 15% SDS–polyacrylamide gels. Pro-
teins were transferred to PVDF membranes. Membranes
were blocked and probed using 5% skim milk, 0.1%
Tween 20 in Tris-buffered saline (TBS) for blocking and
antibody dilutions. Antibody–antigen complexes were
detected using enhanced chemiluminescence (ECL; Am-
ersham International, Buckinghamshire, UK). For antigen
competition experiments, primary antibodies were di-
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vcyc or uninfused GST and used for probing of the
membrane after a 30-min preincubation period.
Size fractionation of BC-3 cell lysates were performed
using a 2.4 ml of Superose 12 PC 3.2/30 column and the
Smart automated protein fractionation minisystem (Phar-
macia, Uppsala, Sweden). Then 50 ml of cell lysate was
loaded onto the column, and 30 fractions of 50 ml each
were collected. The column was calibrated using a na-
tive size marker set (Bio-Rad, Hercules, CA).
Immunoprecipitations and cdk depletion were per-
formed essentially as described (Godden-Kent et al.,
1997). To produce denatured cell lysates, SDS was
added to a final concentration of 5%, and the samples
were heated to 95°C for 5 min. Before immunoprecipita-
tion, the denatured lysates were diluted with 10 volumes
of HB.
RNA preparation and analysis
RNA was extracted from PEL cells using the Microfast
Track mRNA isolation kit (InVitrogen, La Jolla, CA) ac-
cording to the manufacturer’s instructions. Slot blot anal-
ysis was performed essentially as described (Sambrook
et al., 1989). Cloned sequences comprising the full-
length reading frame for ORF 72 (vcyc), ORF16 (vbcl2),
and cellular glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) were used as hybridisation probes.
Probes were generated using the Rediprime II random
prime labeling system (Amersham Pharmacia Biotech).
Reverse transcription was performed using the cDNA
Cycle Kit from InVitrogen. Primers used for the amplifi-
cation of cyclin sequences were 59-ATAGCTGTCCAG-
GAATGCG-39 and 59-GGCAACTGCCAATAACC-39.
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